<code id='677E3728C8'></code><style id='677E3728C8'></style>
    • <acronym id='677E3728C8'></acronym>
      <center id='677E3728C8'><center id='677E3728C8'><tfoot id='677E3728C8'></tfoot></center><abbr id='677E3728C8'><dir id='677E3728C8'><tfoot id='677E3728C8'></tfoot><noframes id='677E3728C8'>

    • <optgroup id='677E3728C8'><strike id='677E3728C8'><sup id='677E3728C8'></sup></strike><code id='677E3728C8'></code></optgroup>
        1. <b id='677E3728C8'><label id='677E3728C8'><select id='677E3728C8'><dt id='677E3728C8'><span id='677E3728C8'></span></dt></select></label></b><u id='677E3728C8'></u>
          <i id='677E3728C8'><strike id='677E3728C8'><tt id='677E3728C8'><pre id='677E3728C8'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:5392
          David Sabatini
          Wikimedia Commons

          Former MIT and Whitehead Institute star biologist David Sabatini, who lost his positions after he was accused of violating sexual harassment policies in 2021, is resuming his science career, taking a post at a Czech research institute in Prague.

          Sabatini, of Cambridge, confirmed in a phone call from Prague that he has accepted a position as a “senior group leader” at the Institute of Organic Chemistry and Biochemistry, known as IOCB Prague. Sabatini said he will be recruiting staff and running a laboratory in the Czech Republic capital to investigate scientific questions in the areas of cell growth and metabolism, similar to his past research in Cambridge.

          advertisement

          “I’m very grateful to be given the opportunity to do science again,” said Sabatini, who began working at the institute last month.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Drugmakers bet big on mRNA for cancer. Why's Biden going in?
          Drugmakers bet big on mRNA for cancer. Why's Biden going in?

          DrugmakersalreadybetbigonmRNAforcancer.NowPresidentBidenisgoingin,too?AnnaMoneymaker/GettyImagesWASH

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Twill hunts for pharma partner to market its depression app

          AlexHogan/STATInanothersignofthebusinessheadwindsfacingprescriptionmentalhealthapps,developerTwillwi